Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia | Disease Landscape & Forecast | G7 | 2021

The launch of several novel therapies, as well as multiple label expansions of premium-priced agents, will fuel significant growth of the non-Hodgkin’s lymphoma (NHL) / chronic lymphocytic leukemia (CLL) therapy market over the 10-year forecast period. Key therapies expected to fuel growth are the approved CAR T-cell therapies Yescarta (Gilead), Kymriah (Novartis), Tecartus (Gilead), and Breyanzi (Bristol Myers Squibb), as well as targeted agents Polivy (Roche), Monjuvi / Minjuvi (MorphoSys / Incyte), Xpovio (Karyopharm Therapeutics), and Zynlonta (ADC Therapeutics). In addition, combinations incorporating the BTK inhibitors Imbruvica (Janssen / AbbVie) and Calquence (AstraZeneca), and the BCL-2 inhibitor Venclexta / Venclyxto (AbbVie / Roche) will enter the market, resulting in a shift away from conventional immunochemotherapy regimens. Notably, the anticipated launch of novel emerging therapies (such as the bispecific antibodies glofitamab [Roche], mosunetuzumab [Roche], epcoritamab [Genmab / AbbVie], and non-covalent BTK inhibitor pirtobrutinib [Loxo Oncology / Eli Lilly]) will further fragment the R/R DLBCL, FL and CLL / SLL patient settings and create intense competition.

Questions Answered

  • Which emerging therapies are the most promising in NHL, and what patient populations will they target? What will be their impact on the NHL market?
  • How will the market share for rituximab change over the 10-year forecast period as a result of biosimilars entry?
  • The NHL therapy market will experience robust growth through 2030. What factors are driving growth in the NHL market? Which drug class will dominate the treatment of NHL? What new classes of agents will emerge over the 10-year forecast period, and what will be their market impact?

Content Highlights

Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, Japan.

Primary research: 19 country-specific interviews with experts and 210 country-specific surveys with hematologist-oncologists treating NHL.

Epidemiology: Diagnosed incidence of follicular lymphoma (FL) (including transformed FL), chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL / SLL), diffuse large B-cell lymphoma (DLBCL), and mantle cell lymphoma (MCL).

Population segments in market forecast: First-line, second-line, third-line, and fourth-line for FL, CLL / SLL, DLBCL, and MCL.

Emerging therapies: Phase I/II: 19 drugs; Phase III / PR: 11 drugs.

Product Description

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Solution Enhancement

Disease Landscape & Forecast will feature continuous updates in 2021 to provide timely insights and analyses as meaningful indication-specific news and events unfold.

Login to access report